PARP1 and neoplasm: For instance, tumor-derived exosomes have been employed to deliver CRISPR/Cas9 systems targeting poly(ADP-ribose) polymerase 1 (PARP-1), yielding potent therapeutic outcomes in solid tumor models (93).